nodes	percent_of_prediction	percent_of_DWPC	metapath
Bromocriptine—DRD5—attention deficit hyperactivity disorder	0.166	0.212	CbGaD
Bromocriptine—ADRA2C—attention deficit hyperactivity disorder	0.157	0.2	CbGaD
Bromocriptine—DRD4—attention deficit hyperactivity disorder	0.0851	0.108	CbGaD
Bromocriptine—HTR1B—attention deficit hyperactivity disorder	0.0756	0.0961	CbGaD
Bromocriptine—DRD3—attention deficit hyperactivity disorder	0.0734	0.0933	CbGaD
Bromocriptine—DRD1—attention deficit hyperactivity disorder	0.072	0.0916	CbGaD
Bromocriptine—ADRA2A—attention deficit hyperactivity disorder	0.0669	0.0851	CbGaD
Bromocriptine—DRD2—attention deficit hyperactivity disorder	0.0508	0.0646	CbGaD
Bromocriptine—HTR2A—attention deficit hyperactivity disorder	0.0392	0.0499	CbGaD
Bromocriptine—HTR7—locus ceruleus—attention deficit hyperactivity disorder	0.00451	0.0844	CbGeAlD
Bromocriptine—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00281	0.0526	CbGeAlD
Bromocriptine—HTR7—autonomic nervous system—attention deficit hyperactivity disorder	0.0024	0.0448	CbGeAlD
Bromocriptine—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.0015	0.028	CbGeAlD
Bromocriptine—HTR6—forebrain—attention deficit hyperactivity disorder	0.0012	0.0225	CbGeAlD
Bromocriptine—DRD5—forebrain—attention deficit hyperactivity disorder	0.00117	0.0219	CbGeAlD
Bromocriptine—ADRA1D—forebrain—attention deficit hyperactivity disorder	0.000939	0.0175	CbGeAlD
Bromocriptine—Ergoloid mesylate—DRD1—attention deficit hyperactivity disorder	0.000895	0.161	CrCbGaD
Bromocriptine—DRD1—forebrain—attention deficit hyperactivity disorder	0.000894	0.0167	CbGeAlD
Bromocriptine—DRD4—brain—attention deficit hyperactivity disorder	0.000737	0.0138	CbGeAlD
Bromocriptine—HTR1B—forebrain—attention deficit hyperactivity disorder	0.000725	0.0135	CbGeAlD
Bromocriptine—Dihydroergotamine—HTR1B—attention deficit hyperactivity disorder	0.000712	0.128	CrCbGaD
Bromocriptine—HTR1D—forebrain—attention deficit hyperactivity disorder	0.000702	0.0131	CbGeAlD
Bromocriptine—HTR2C—forebrain—attention deficit hyperactivity disorder	0.000695	0.013	CbGeAlD
Bromocriptine—ADRB1—forebrain—attention deficit hyperactivity disorder	0.000682	0.0127	CbGeAlD
Bromocriptine—DRD3—nervous system—attention deficit hyperactivity disorder	0.000678	0.0127	CbGeAlD
Bromocriptine—DRD3—central nervous system—attention deficit hyperactivity disorder	0.000653	0.0122	CbGeAlD
Bromocriptine—HTR6—nervous system—attention deficit hyperactivity disorder	0.000653	0.0122	CbGeAlD
Bromocriptine—HTR2B—forebrain—attention deficit hyperactivity disorder	0.000653	0.0122	CbGeAlD
Bromocriptine—DRD5—nervous system—attention deficit hyperactivity disorder	0.000635	0.0119	CbGeAlD
Bromocriptine—Ergoloid mesylate—DRD2—attention deficit hyperactivity disorder	0.000631	0.114	CrCbGaD
Bromocriptine—Dihydroergotamine—ADRA2A—attention deficit hyperactivity disorder	0.00063	0.113	CrCbGaD
Bromocriptine—HTR6—central nervous system—attention deficit hyperactivity disorder	0.000628	0.0117	CbGeAlD
Bromocriptine—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.000613	0.0115	CbGeAlD
Bromocriptine—DRD5—central nervous system—attention deficit hyperactivity disorder	0.000612	0.0114	CbGeAlD
Bromocriptine—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.000593	0.0111	CbGeAlD
Bromocriptine—DRD1—midbrain—attention deficit hyperactivity disorder	0.000591	0.011	CbGeAlD
Bromocriptine—HTR1A—forebrain—attention deficit hyperactivity disorder	0.000585	0.0109	CbGeAlD
Bromocriptine—ADRB1—cardiovascular system—attention deficit hyperactivity disorder	0.000577	0.0108	CbGeAlD
Bromocriptine—HTR7—forebrain—attention deficit hyperactivity disorder	0.000559	0.0104	CbGeAlD
Bromocriptine—HTR2B—cardiovascular system—attention deficit hyperactivity disorder	0.000552	0.0103	CbGeAlD
Bromocriptine—Methylergometrine—DRD1—attention deficit hyperactivity disorder	0.000542	0.0976	CrCbGaD
Bromocriptine—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000539	0.0101	CbGeAlD
Bromocriptine—DRD2—forebrain—attention deficit hyperactivity disorder	0.000528	0.00988	CbGeAlD
Bromocriptine—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.000521	0.00974	CbGeAlD
Bromocriptine—DRD3—brain—attention deficit hyperactivity disorder	0.000518	0.00969	CbGeAlD
Bromocriptine—ADRA1D—nervous system—attention deficit hyperactivity disorder	0.00051	0.00952	CbGeAlD
Bromocriptine—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000502	0.00937	CbGeAlD
Bromocriptine—HTR6—brain—attention deficit hyperactivity disorder	0.000499	0.00933	CbGeAlD
Bromocriptine—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.000495	0.00924	CbGeAlD
Bromocriptine—ADRA1D—central nervous system—attention deficit hyperactivity disorder	0.000491	0.00917	CbGeAlD
Bromocriptine—DRD5—brain—attention deficit hyperactivity disorder	0.000486	0.00908	CbGeAlD
Bromocriptine—DRD1—nervous system—attention deficit hyperactivity disorder	0.000486	0.00908	CbGeAlD
Bromocriptine—HTR1B—midbrain—attention deficit hyperactivity disorder	0.000479	0.00894	CbGeAlD
Bromocriptine—Methysergide—HTR1B—attention deficit hyperactivity disorder	0.000475	0.0855	CrCbGaD
Bromocriptine—HTR7—cardiovascular system—attention deficit hyperactivity disorder	0.000473	0.00883	CbGeAlD
Bromocriptine—DRD1—central nervous system—attention deficit hyperactivity disorder	0.000467	0.00874	CbGeAlD
Bromocriptine—HTR1D—midbrain—attention deficit hyperactivity disorder	0.000463	0.00866	CbGeAlD
Bromocriptine—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000459	0.00858	CbGeAlD
Bromocriptine—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000456	0.00852	CbGeAlD
Bromocriptine—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.00041	0.00766	CbGeAlD
Bromocriptine—ADRA1B—brain—attention deficit hyperactivity disorder	0.000398	0.00744	CbGeAlD
Bromocriptine—HTR1B—nervous system—attention deficit hyperactivity disorder	0.000393	0.00735	CbGeAlD
Bromocriptine—ADRA1D—brain—attention deficit hyperactivity disorder	0.000389	0.00728	CbGeAlD
Bromocriptine—HTR1A—midbrain—attention deficit hyperactivity disorder	0.000386	0.00722	CbGeAlD
Bromocriptine—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000381	0.00712	CbGeAlD
Bromocriptine—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000379	0.00708	CbGeAlD
Bromocriptine—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000377	0.00705	CbGeAlD
Bromocriptine—DRD1—brain—attention deficit hyperactivity disorder	0.000371	0.00694	CbGeAlD
Bromocriptine—ADRB1—nervous system—attention deficit hyperactivity disorder	0.00037	0.00692	CbGeAlD
Bromocriptine—HTR7—midbrain—attention deficit hyperactivity disorder	0.000369	0.0069	CbGeAlD
Bromocriptine—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000367	0.00685	CbGeAlD
Bromocriptine—Ergotamine—HTR1B—attention deficit hyperactivity disorder	0.000367	0.066	CrCbGaD
Bromocriptine—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.000363	0.00679	CbGeAlD
Bromocriptine—ADRB1—central nervous system—attention deficit hyperactivity disorder	0.000356	0.00666	CbGeAlD
Bromocriptine—HTR2B—nervous system—attention deficit hyperactivity disorder	0.000354	0.00662	CbGeAlD
Bromocriptine—DRD2—midbrain—attention deficit hyperactivity disorder	0.000349	0.00652	CbGeAlD
Bromocriptine—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000349	0.00651	CbGeAlD
Bromocriptine—HTR2B—central nervous system—attention deficit hyperactivity disorder	0.000341	0.00638	CbGeAlD
Bromocriptine—ADRA2C—midbrain—attention deficit hyperactivity disorder	0.000339	0.00634	CbGeAlD
Bromocriptine—Ergotamine—ADRA2A—attention deficit hyperactivity disorder	0.000325	0.0584	CrCbGaD
Bromocriptine—HTR1A—nervous system—attention deficit hyperactivity disorder	0.000317	0.00593	CbGeAlD
Bromocriptine—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000306	0.00571	CbGeAlD
Bromocriptine—HTR7—nervous system—attention deficit hyperactivity disorder	0.000303	0.00567	CbGeAlD
Bromocriptine—HTR1B—brain—attention deficit hyperactivity disorder	0.000301	0.00562	CbGeAlD
Bromocriptine—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.000299	0.00558	CbGeAlD
Bromocriptine—Methylergometrine—HTR2A—attention deficit hyperactivity disorder	0.000295	0.0532	CrCbGaD
Bromocriptine—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000295	0.00551	CbGeAlD
Bromocriptine—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000293	0.00547	CbGeAlD
Bromocriptine—HTR7—central nervous system—attention deficit hyperactivity disorder	0.000292	0.00546	CbGeAlD
Bromocriptine—HTR1D—brain—attention deficit hyperactivity disorder	0.000291	0.00544	CbGeAlD
Bromocriptine—HTR2C—brain—attention deficit hyperactivity disorder	0.000288	0.00539	CbGeAlD
Bromocriptine—DRD2—nervous system—attention deficit hyperactivity disorder	0.000287	0.00536	CbGeAlD
Bromocriptine—HTR7—cerebellum—attention deficit hyperactivity disorder	0.000286	0.00534	CbGeAlD
Bromocriptine—ADRB1—brain—attention deficit hyperactivity disorder	0.000283	0.00529	CbGeAlD
Bromocriptine—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000282	0.00527	CbGeAlD
Bromocriptine—ADRA2C—nervous system—attention deficit hyperactivity disorder	0.000279	0.00521	CbGeAlD
Bromocriptine—DRD2—central nervous system—attention deficit hyperactivity disorder	0.000276	0.00516	CbGeAlD
Bromocriptine—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000275	0.00515	CbGeAlD
Bromocriptine—HTR2B—brain—attention deficit hyperactivity disorder	0.000271	0.00506	CbGeAlD
Bromocriptine—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000271	0.00506	CbGeAlD
Bromocriptine—DRD2—cerebellum—attention deficit hyperactivity disorder	0.00027	0.00505	CbGeAlD
Bromocriptine—ADRA2C—central nervous system—attention deficit hyperactivity disorder	0.000268	0.00502	CbGeAlD
Bromocriptine—ADRA2C—cerebellum—attention deficit hyperactivity disorder	0.000262	0.00491	CbGeAlD
Bromocriptine—Methysergide—HTR2A—attention deficit hyperactivity disorder	0.000246	0.0444	CrCbGaD
Bromocriptine—Ergotamine—DRD2—attention deficit hyperactivity disorder	0.000246	0.0443	CrCbGaD
Bromocriptine—HTR1A—brain—attention deficit hyperactivity disorder	0.000243	0.00454	CbGeAlD
Bromocriptine—HTR7—brain—attention deficit hyperactivity disorder	0.000232	0.00433	CbGeAlD
Bromocriptine—HTR2A—midbrain—attention deficit hyperactivity disorder	0.00023	0.0043	CbGeAlD
Bromocriptine—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000228	0.00427	CbGeAlD
Bromocriptine—ADRA1A—brain—attention deficit hyperactivity disorder	0.000224	0.00418	CbGeAlD
Bromocriptine—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000223	0.00416	CbGeAlD
Bromocriptine—DRD2—brain—attention deficit hyperactivity disorder	0.000219	0.0041	CbGeAlD
Bromocriptine—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000214	0.004	CbGeAlD
Bromocriptine—ADRA2C—brain—attention deficit hyperactivity disorder	0.000213	0.00398	CbGeAlD
Bromocriptine—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000209	0.00391	CbGeAlD
Bromocriptine—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000193	0.00361	CbGeAlD
Bromocriptine—Ergotamine—HTR2A—attention deficit hyperactivity disorder	0.00019	0.0343	CrCbGaD
Bromocriptine—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000189	0.00354	CbGeAlD
Bromocriptine—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000182	0.0034	CbGeAlD
Bromocriptine—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000178	0.00333	CbGeAlD
Bromocriptine—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000175	0.00327	CbGeAlD
Bromocriptine—ADRA2A—brain—attention deficit hyperactivity disorder	0.00017	0.00318	CbGeAlD
Bromocriptine—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000169	0.00315	CbGeAlD
Bromocriptine—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000151	0.00282	CbGeAlD
Bromocriptine—HTR2A—brain—attention deficit hyperactivity disorder	0.000145	0.0027	CbGeAlD
Bromocriptine—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000124	0.00232	CbGeAlD
Bromocriptine—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000119	0.00223	CbGeAlD
Bromocriptine—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000117	0.00218	CbGeAlD
Bromocriptine—ABCB1—brain—attention deficit hyperactivity disorder	9.48e-05	0.00177	CbGeAlD
Bromocriptine—HTR7—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.89e-06	5.75e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	8.86e-06	5.73e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	8.85e-06	5.73e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.83e-06	5.71e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	8.83e-06	5.71e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.81e-06	5.7e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	8.8e-06	5.69e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	8.76e-06	5.67e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	8.74e-06	5.65e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	8.72e-06	5.64e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	8.68e-06	5.62e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	8.65e-06	5.59e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.65e-06	5.59e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.57e-06	5.54e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.56e-06	5.54e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	8.54e-06	5.53e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.51e-06	5.51e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.5e-06	5.5e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	8.44e-06	5.46e-05	CbGpPWpGaD
Bromocriptine—DRD1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	8.43e-06	5.46e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.41e-06	5.44e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.4e-06	5.43e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.33e-06	5.39e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	8.32e-06	5.38e-05	CbGpPWpGaD
Bromocriptine—DRD3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	8.32e-06	5.38e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.3e-06	5.37e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.29e-06	5.36e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.23e-06	5.33e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.19e-06	5.3e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	8.17e-06	5.29e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.16e-06	5.28e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.16e-06	5.28e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.15e-06	5.27e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	8.14e-06	5.27e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	8.12e-06	5.26e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.12e-06	5.26e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.09e-06	5.24e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.08e-06	5.23e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.06e-06	5.22e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.06e-06	5.21e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.05e-06	5.21e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.99e-06	5.17e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	7.95e-06	5.15e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.93e-06	5.13e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	7.93e-06	5.13e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.93e-06	5.13e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.93e-06	5.13e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	7.84e-06	5.08e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.83e-06	5.07e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.83e-06	5.07e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.83e-06	5.07e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.82e-06	5.06e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.8e-06	5.05e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.8e-06	5.05e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.76e-06	5.02e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.66e-06	4.96e-05	CbGpPWpGaD
Bromocriptine—ADRB1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.58e-06	4.91e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.57e-06	4.9e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.56e-06	4.89e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.56e-06	4.89e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.55e-06	4.89e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.51e-06	4.86e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.5e-06	4.86e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.5e-06	4.85e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.47e-06	4.83e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	7.46e-06	4.83e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.46e-06	4.83e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.45e-06	4.82e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.44e-06	4.82e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.43e-06	4.81e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	7.39e-06	4.78e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.35e-06	4.76e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.34e-06	4.75e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	7.34e-06	4.75e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.29e-06	4.72e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.28e-06	4.71e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.28e-06	4.71e-05	CbGpPWpGaD
Bromocriptine—HTR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.25e-06	4.69e-05	CbGpPWpGaD
Bromocriptine—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.21e-06	4.67e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	7.2e-06	4.66e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.18e-06	4.64e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.14e-06	4.62e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.13e-06	4.62e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.07e-06	4.57e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.05e-06	4.56e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.02e-06	4.54e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.02e-06	4.54e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.99e-06	4.52e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.93e-06	4.49e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.93e-06	4.48e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.93e-06	4.48e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.91e-06	4.47e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.88e-06	4.46e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.85e-06	4.43e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.85e-06	4.43e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.84e-06	4.43e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.84e-06	4.43e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.82e-06	4.41e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.82e-06	4.41e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.82e-06	4.41e-05	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.81e-06	4.41e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.79e-06	4.39e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.74e-06	4.36e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.63e-06	4.29e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.6e-06	4.27e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.6e-06	4.27e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.59e-06	4.26e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.57e-06	4.25e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.55e-06	4.24e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.5e-06	4.2e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.46e-06	4.18e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.42e-06	4.16e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.37e-06	4.12e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.37e-06	4.12e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.37e-06	4.12e-05	CbGpPWpGaD
Bromocriptine—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.37e-06	4.12e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.36e-06	4.12e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.34e-06	4.1e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.31e-06	4.08e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.31e-06	4.08e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	6.3e-06	4.08e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.27e-06	4.06e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.25e-06	4.05e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.23e-06	4.03e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.18e-06	4e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.14e-06	3.97e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.14e-06	3.97e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.13e-06	3.97e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.13e-06	3.97e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.11e-06	3.95e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.04e-06	3.91e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.04e-06	3.91e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.01e-06	3.89e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.99e-06	3.88e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.96e-06	3.86e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.96e-06	3.86e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.96e-06	3.86e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.94e-06	3.85e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.93e-06	3.84e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.89e-06	3.81e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	5.88e-06	3.81e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.85e-06	3.79e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.84e-06	3.78e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.81e-06	3.76e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.78e-06	3.74e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.77e-06	3.73e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.77e-06	3.73e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.75e-06	3.72e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.75e-06	3.72e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.7e-06	3.69e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.68e-06	3.67e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.57e-06	3.61e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.57e-06	3.6e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	5.56e-06	3.6e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.55e-06	3.59e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.53e-06	3.58e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	5.52e-06	3.57e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.48e-06	3.55e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.39e-06	3.49e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.37e-06	3.48e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.36e-06	3.47e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.36e-06	3.47e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.31e-06	3.43e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.3e-06	3.43e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.29e-06	3.42e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.26e-06	3.4e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.25e-06	3.4e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.24e-06	3.39e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.22e-06	3.38e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.22e-06	3.38e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.2e-06	3.36e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.18e-06	3.35e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	5.16e-06	3.34e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.16e-06	3.34e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.15e-06	3.33e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.11e-06	3.3e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.11e-06	3.3e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	5.07e-06	3.28e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.04e-06	3.26e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.03e-06	3.25e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.98e-06	3.23e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.83e-06	3.12e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.8e-06	3.11e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.8e-06	3.1e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	4.78e-06	3.09e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.72e-06	3.05e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.7e-06	3.04e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.69e-06	3.03e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.6e-06	2.98e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.52e-06	2.93e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	4.52e-06	2.92e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	4.49e-06	2.9e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.46e-06	2.89e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.46e-06	2.89e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.37e-06	2.83e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.12e-06	2.67e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	4.12e-06	2.66e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.12e-06	2.66e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.07e-06	2.63e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	4.05e-06	2.62e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.03e-06	2.61e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.92e-06	2.54e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.89e-06	2.52e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.87e-06	2.5e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.76e-06	2.44e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.76e-06	2.44e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.7e-06	2.4e-05	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.61e-06	2.33e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.42e-06	2.21e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.29e-06	2.13e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.29e-06	2.13e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.18e-06	2.06e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	3.18e-06	2.06e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.13e-06	2.03e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	3.13e-06	2.02e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	3.12e-06	2.02e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	3.1e-06	2.01e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.06e-06	1.98e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.91e-06	1.88e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.78e-06	1.8e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.78e-06	1.8e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.76e-06	1.79e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.71e-06	1.75e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.66e-06	1.72e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.54e-06	1.64e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.54e-06	1.64e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	2.49e-06	1.61e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	2.48e-06	1.6e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.42e-06	1.56e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.4e-06	1.55e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.4e-06	1.55e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	2.39e-06	1.54e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.36e-06	1.53e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.36e-06	1.53e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.15e-06	1.39e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.14e-06	1.38e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.06e-06	1.33e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.05e-06	1.33e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.99e-06	1.29e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.96e-06	1.27e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	1.94e-06	1.25e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	1.92e-06	1.25e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	1.91e-06	1.24e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.81e-06	1.17e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.78e-06	1.15e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.74e-06	1.13e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.62e-06	1.05e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	1.34e-06	8.67e-06	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	1.07e-06	6.92e-06	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	8.25e-07	5.34e-06	CbGpPWpGaD
